<DOC>
	<DOCNO>NCT02775370</DOCNO>
	<brief_summary>This non-randomized , phase II , open label study Apatinib Mesylate patient Head neck metastatic adenoid cystic carcinoma ( ACC ) . The primary purpose study evaluate efficacy safety Apatinib Mesylate patient ACC .</brief_summary>
	<brief_title>A Study Apatinib Metastatic Adenoid Cystic Carcinoma Head Neck</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Adenoid Cystic</mesh_term>
	<criteria>1 . Histologically cytologically confirm adenoid cystic carcinoma 2 . Metastatic disease document show progression scan ( CT , MRI ) compare previous scan take time past . Progression must document accord RECIST criterion . 3 . Presence least one measurable target lesion evaluation accord RECIST criterion 4 . Disease amenable surgery , radiation combine modality therapy curative intent previously treat chemotherapy 5 . 18 year old 6 . Karnofsky score 60 7 . Previous treatment chemotherapy , target agent , locoregional therapy ( e.g . chemoembolization ) permit provide toxicity resolve &lt; = grade 1 study entry last treatment least 4 week prior baseline assessment . 8 . Adequate organ function 9 . A patient willingness comply study protocol study period capable comply 10 . A patient sign informed consent prior participation study understand right withdrawal participation study time without disadvantage . 1 . A patient measurable disease 2 . Prior chemotherapy , radiation therapy surgery within 4 week prior study entry except palliative radiotherapy nontarget lesion ( within 2 week prior study entry ) 3 . A patient previous active passive immunotherapy 4 . A patient intestinal obstruction impend obstruction , recent active upper GI bleed 5 . A pregnant lactating patient 6 . A patient childbearing potential without tested pregnancy baseline test positive . ( A postmenopausal woman amenorrhea period least 12 month longer consider nonchildbearing potential ) 7 . A man woman childbearing potential willingness use contraceptive measure study 8 . A patient history another malignant disease within past 5 year , except curatively treat basal cell carcinoma skin cervical carcinoma situ . 9 . A patient history uncontrolled seizure , central nervous system disorder psychiatric disorder consider clinically significant investigator would prohibit understanding informed consent may consider interfere compliance administration study medication . 10 . A patient clinically significant heart disease ( e.g . congestive heart failure , symptomatic coronary artery disease , cardiac arrhythmia , etc ) myocardial infarction within past 12 month . 11 . Ongoing cardiac arrhythmia grade &gt; = 2 , atrial fibrillation grade , QTc interval &gt; 450 msec male &gt; 470 msec female . 12 . A patient interstitial pneumonia diffuse symptomatic fibrosis lung 13 . A patient organ transplantation require immunosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>